These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 21223255)
1. The non-relapse mortality rate for patients with diffuse large B-cell lymphoma is greater than relapse mortality 8 years after autologous stem cell transplantation and is significantly higher than mortality rates of population controls. Hill BT; Rybicki L; Bolwell BJ; Smith S; Dean R; Kalaycio M; Pohlman B; Tench S; Sobecks R; Andresen S; Copelan E; Sweetenham J Br J Haematol; 2011 Mar; 152(5):561-9. PubMed ID: 21223255 [TBL] [Abstract][Full Text] [Related]
2. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B. Nademanee A; Forman SJ Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658 [TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
4. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
5. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Sirvent A; Dhedin N; Michallet M; Mounier N; Faucher C; Yakoub-Agha I; Mohty M; Robin M; Tabrizi R; Clement L; Bilger K; Larosa F; Contentin N; Huyn A; François S; Bulabois CE; Ceballos P; Bourrhis JH; Buzyn A; Cornillon J; Guillerm G; de Revel T; Bay JO; Guilhot F; Milpied N Biol Blood Marrow Transplant; 2010 Jan; 16(1):78-85. PubMed ID: 19744569 [TBL] [Abstract][Full Text] [Related]
6. Involved field radiation after autologous stem cell transplant for diffuse large B-cell lymphoma in the rituximab era. Biswas T; Dhakal S; Chen R; Hyrien O; Bernstein S; Friedberg JW; Fisher RI; Liesveld J; Phillips G; Constine LS Int J Radiat Oncol Biol Phys; 2010 May; 77(1):79-85. PubMed ID: 19647953 [TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508 [TBL] [Abstract][Full Text] [Related]
8. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003. Jantunen E; Itälä M; Siitonen T; Koivunen E; Leppä S; Juvonen E; Kuittinen O; Lehtinen T; Koistinen P; Nyman H; Nousiainen T; Volin L; Remes K Eur J Haematol; 2006 Aug; 77(2):114-9. PubMed ID: 16856906 [TBL] [Abstract][Full Text] [Related]
9. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A; Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647 [TBL] [Abstract][Full Text] [Related]
10. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255 [TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Jantunen E; Canals C; Rambaldi A; Ossenkoppele G; Allione B; Blaise D; Conde E; Tilly H; Cook G; Clark F; Gallamini A; Haynes A; Mounier N; Dreger P; Pfreundschuh M; Sureda A; Haematologica; 2008 Dec; 93(12):1837-42. PubMed ID: 18838474 [TBL] [Abstract][Full Text] [Related]
12. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic results in patients with relapsed diffuse large B cell Non-Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation. Ferrara F; Viola A; Copia C; Schiavone EM; Celentano M; Pollio F; D'Amico MR; Palmieri S Hematol Oncol; 2006 Jun; 24(2):73-7. PubMed ID: 16550628 [TBL] [Abstract][Full Text] [Related]
14. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284 [TBL] [Abstract][Full Text] [Related]
15. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle. Brice P; Bouabdallah R; Moreau P; Divine M; André M; Aoudjane M; Fleury J; Anglaret B; Baruchel A; Sensebe L; Colombat P Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251 [TBL] [Abstract][Full Text] [Related]
17. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Rigacci L; Puccini B; Dodero A; Iacopino P; Castagna L; Bramanti S; Ciceri F; Fanin R; Rambaldi A; Falda M; Milone G; Guidi S; Martelli MF; Mazza P; Oneto R; Bosi A; Ann Hematol; 2012 Jun; 91(6):931-9. PubMed ID: 22245922 [TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144 [TBL] [Abstract][Full Text] [Related]